Aurora Cannabis Inc (TSE:ACB) Senior Officer Allan John Cleiren sold 33,000 shares of the company’s stock in a transaction dated Monday, April 22nd. The shares were sold at an average price of C$12.12, for a total transaction of C$399,960.00. Following the completion of the transaction, the insider now directly owns 51,120 shares in the company, valued at approximately C$619,574.40.

Shares of ACB traded up C$0.17 during mid-day trading on Monday, hitting C$12.20. 4,770,757 shares of the company’s stock were exchanged, compared to its average volume of 16,714,760. The stock has a market capitalization of $12.17 billion and a PE ratio of -123.23. Aurora Cannabis Inc has a fifty-two week low of C$5.29 and a fifty-two week high of C$16.24. The company has a debt-to-equity ratio of 8.08, a quick ratio of 1.89 and a current ratio of 3.31.

Aurora Cannabis (TSE:ACB) last issued its quarterly earnings results on Monday, February 11th. The company reported C($0.05) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of C($0.06) by C$0.01. The business had revenue of C$54.18 million for the quarter, compared to analyst estimates of C$52.13 million. On average, sell-side analysts predict that Aurora Cannabis Inc will post 0.0299747682090031 earnings per share for the current year.

A number of research analysts have commented on the stock. Cowen reaffirmed an “outperform” rating and issued a C$14.00 target price on shares of Aurora Cannabis in a research report on Tuesday, March 5th. Eight Capital decreased their target price on shares of Aurora Cannabis from C$17.00 to C$15.00 in a research report on Wednesday, January 9th. Jefferies Financial Group reaffirmed a “buy” rating and issued a C$12.00 target price on shares of Aurora Cannabis in a research report on Monday, February 25th. Bank of America reaffirmed a “buy” rating and issued a C$15.00 target price on shares of Aurora Cannabis in a research report on Wednesday, April 17th. Finally, Seaport Global Securities reissued a “neutral” rating on shares of Aurora Cannabis in a research report on Thursday, February 21st. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus target price of C$13.80.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Marea Informative and is owned by of Marea Informative. If you are accessing this report on another publication, it was illegally copied and republished in violation of U.S. & international copyright law. The original version of this report can be read at https://www.mareainformativa.com/news/2019/04/22/aurora-cannabis-inc-acb-senior-officer-allan-john-cleiren-sells-33000-shares.html.

About Aurora Cannabis

Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis, and hemp production, derivatives, home cultivation, wholesale and retail distribution.

Further Reading: What are the advantages of the Stochastic Momentum Index?

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.